Redeye endorses the results from ISAB’s first-in-human clinical study of its PreciseInhale system.
Redeye provides an update in relation to ISAB’s Q4 2023 report.
Redeye endorses ISAB’s new partnership with the inhalation development service provider Actarmo Medical.
Redeye provides an update in relation to ISAB’s Q3 2023 report.
Redeye endorses Inhalation Sciences’ order worth approximately SEK3.
Redeye is positive about ISAB’s new order worth EUR188,900 from a global generics manufacturer.
Redeye endorses ISAB's collaboration with a leading Indian pharmaceutical company, recognizing it as a significant stride into the Indian ma...
Redeye provides an update in relation to ISAB’s Q2 2023 report.
Redeye is positive about the last week’s strong order flow, which is highly important for the company’s journey to become cash-flow positive...
Redeye provides an update in relation to ISAB’s Q1 2023 report.
Redeye comments on ISAB’s rights issue outcome, which was subscribed to approximately 23% in total.
Redeye endorses the green light to start the experimental phase of the FDA dissolution research project aiming to validate DissolvIt as an F...
Redeye comments on ISAB’s rights issue announcement of approximately SEK17.
Redeye provides an update in relation to ISAB’s Q4 2022 report.
Redeye endorses ISAB’s two new orders worth SEK1.9m and SEK0.
Redeye comments on Inhalation Sciences’ Q3 2022 report.
Redeye is positive for ISAB’s continued high sales activity.
Redeye is positive about the newly signed IRS contract of SEK 806,000 with a returning customer.
Redeye endorses ISAB’s new IRS contract worth SEK 1.
Redeye endorses that ISAB has received another order from a leading global pharmaceutical company.
Redeye comments on Inhalation Sciences Q2’22 report.
Redeye is positive about the news that the FDA has approved ISAB’s proposal for a research study aiming to validate the in vitro lung simula...
Redeye endorses ISAB’s new IRS order from a US client worth SEK 1.
Redeye comments on the news regarding ISAB's latest IRS order worth SEK 518,000.
Redeye is encouraged by the news that ISAB´s collaboration with RISE has been successful on the first proposal regarding a global project on...
Manoush Masarrat, CEO at Inhalation Sciences, held a strategy update at Redeye on May 24.
Redeye is encouraged to learn that ISAB has received a credit line of SEK 10m from a consortium of lenders to keep the company financed over...
Redeye comments on ISAB’s Q1’22 report. The company has seen a continued high interest for its IRS business during the first quarter and wit...
Redeye endorses ISAB receiving positive feedback from the FDA regarding its white paper proposal submitted in January this year.
Redeye endorses ISAB signing two new distribution agreements with Omicron Research Ltd and Quantaflux Industrial Co.
Redeye endorses ISAB signing yet another IRS contract worth around SEK 773,000 (EUR 74,000).
Redeye returns with a more detailed take on ISAB’s Q4’21 report.
Redeye provides its initial comments on Inhalation Sciences Q4’21 report.
Redeye endorses ISAB signing a new contract worth approximately SEK 0.
Inhalation Sciences, som utvecklar aerosolgenererings-systemet PreciseInhale, har haft det trögt med försäljningen under pandemin.
